Sagimet Biosciences Inc.

NASDAQ: SGMT · Healthcare · Biotechnology

PublicHQ San Mateo, CA · San MateoCIK 0001400118Reports USD

#796 of 1,418 Healthcare companies by revenue

EA Score

36D

FH 47DQ 20GM —SS 38

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$51.0M

Employees

as of 2026-08-13

Market cap

$305.9M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.0M$2.0M2023

Net income-$51.0M-$51.0M2025

Operating income-$56.9M-$56.9M2025

Total assets$116.5M$116.5M2025

Liabilities$5.7M$5.7M2023

Equity$111.4M$111.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Sagimet Biosciences Inc.’s revenue?

Sagimet Biosciences Inc. booked $2.0M in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -2551.9% net margin.

Peers · Healthcare

Nutriband Inc.52D Dianthus Therapeutics, Inc.49D Cocrystal Pharma, Inc.31D Oramed Pharmaceuticals Inc.61C Rapid Dose Therapeutics Corp.38D Pressure BioSciences, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEODavid Happel

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Mateo, CA

ExchangeNASDAQ: SGMT

Employees16

IPO date2023-07-14

Latest filings

8-K2026-08-13 8-K2026-08-11 10-Q2026-08-11 8-K2026-07-21 8-K2026-06-12 8-K2026-06-03 10-Q2026-05-12 8-K2026-05-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.